TOKYO, JAPAN - December 13, 2017 - Terumo Corporation (TSE: 4543) today announced that it will construct a new building for manufacturing interventional systems products on the property of Terumo Yamaguchi Corporation. Terumo will hire approximately 700 associates and invest a total of approximately 30 billion yen in the facility. Construction work is scheduled for June 2018 to October 2019, and operations are scheduled to commence in April 2021.
Terumo Yamaguchi manufactures access guidewires used in interventional procedures. The new building will be the company's third such structure. The company plans to increase the number of guidewire products it produces, as well as its total production capacity. The area of the new building will be approximately 50,000 square meters, or over three times the size of the site's first building, which currently manufactures guidewires.
Terumo has "Strengthen Global Operations" as one of key initiatives towards sustainable growth. The new building will strengthen production capacity in a growing field and optimize production on a global and group basis. The Terumo Interventional Systems Division leads Terumo group in revenue growth, and the construction is expected to support business growth in the globally growing interventional market.
As a global corporation with unique excellence, Terumo aims to become a top brand trusted in medical settings all over the world, through providing "Total Quality": high quality in all aspects of product, supply, and service.
Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 28,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.